

EMA/629584/2022

European Medicines Agency decision P/0261/2022

of 15 July 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510) (EMA-003115-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0261/2022

of 15 July 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510) (EMA-003115-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by SK Chemicals GmbH on 17 September 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2022, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510), emulsion and suspension for emulsion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510), emulsion and suspension for emulsion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to SK Chemicals GmbH, 77 Mergenthalerallee, 65760 – Eschborn, Germany.

EMA/PDCO/260802/2022
Amsterdam, 24 June 2022

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-003115-PIP01-21

Scope of the application

Active substance(s):

Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510)

Condition(s):

Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Emulsion and suspension for emulsion for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

SK Chemicals GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, SK Chemicals GmbH submitted for agreement to the European Medicines Agency on 17 September 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 22 November 2021.

Supplementary information was provided by the applicant on 25 April 2022. The applicant proposed modifications to the paediatric investigation plan .

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Paediatric Committee member Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Prevention of coronavirus disease 2019 (COVID-19)

2.1.1. Indication(s) targeted by the PIP

Prevention of coronavirus disease 2019 (COVID-19)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Emulsion and suspension for emulsion for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Randomised, observer-blind, controlled study to assess the reactogenicity, safety and immunogenicity of SARS-CoV-2 recombinant protein nanoparticle vaccine (adjuvanted with AS03) (GBP510) in adolescents from 12 years to less than 18 years of age for the prevention of COVID-19. Study 2 Randomised, observer-blind, controlled study including an open-label non-controlled dose-finding part to assess the reactogenicity, safety and immunogenicity of SARS-CoV-2 recombinant protein nanoparticle vaccine (adjuvanted with AS03) (GBP510) in adolescents from birth to less than 12 years of age for the prevention of COVID-19. Study 3 Open-label study to assess the reactogenicity, safety and immunogenicity and of SARS-CoV-2 recombinant protein nanoparticle vaccine (adjuvanted with AS03) (GBP510) in immunocompromised children from birth to less than 18 years of age for the prevention of COVID-19.

Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes